September 26, 2024 09:00 PM EDT
Startups
Special

End­points 11 win­ner Li­for­di Im­munother­a­peu­tics: Us­ing an­ti­bod­ies to de­liv­er po­tent steroids di­rect­ly to im­mune cells

Ryan Cross

Senior Science Correspondent

↑
  • CEO Arthur Tzian­a­bos
  • To­tal raised $70 mil­lion
  • Head­quar­ters Burling­ton, MA

As a young sci­en­tist, Jay Roth­stein asked fel­low im­mu­nol­o­gists what …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

FDA ap­proves Dupix­ent in COPD, open­ing ‘next chap­ter’ for Sanofi and Re­gen­eron’s best­seller

Steve Davis leaves Aca­dia, re­placed by Bris­tol My­ers alum; For­mer J&J ex­ec to lead R&D at No­vavax

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times